ID   K-3508
AC   CVCL_B7RT
DR   Wikidata; Q112929935
RX   PubMed=18802091;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:4932; HLA-B (Note=Allele B*35:08).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Omics: Proteomics; HLA class I peptidome.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 8
//
RX   PubMed=18802091; DOI=10.4049/jimmunol.181.7.4874;
RA   Escobar H., Crockett D.K., Reyes-Vargas E., Baena A., Rockwood A.L.,
RA   Jensen P.E., Delgado J.C.;
RT   "Large scale mass spectrometric profiling of peptides eluted from HLA
RT   molecules reveals N-terminal-extended peptide motifs.";
RL   J. Immunol. 181:4874-4882(2008).
//